Fig. 4From: Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectivesAn overview of irAEs in patients with TETs receiving PD-1/PD-L1 inhibitors. Immunotherapy is systemically administered to affect not only tumor progression but also the whole immune system, including central tolerance in the thymus and peripheral immune homeostasis. irAEs: Immune-related adverse events; TETs: Thymic epithelial tumorsBack to article page